Today's announcement was actually for PD1-Vaxx and not HER-Vaxx. It's my understanding is that PD1-Vaxx is based on the same delivery method as HER-Vaxx using B cells to provoke a vaccine/immune response but the difference is that the drugs target different sites in the cells.
So, IMU has 4 potentially major drugs in the pipeline (HER-Vaxx, PD1-Vaxx, CheckVacc and Vaxinnia). I believe today's announcement was more a reminder of the diversity of the pipeline and the broader application of the B cell platform.
If all 4 were to be a success, what price would you put on a company with 4 drugs that would snare a fair chunk of what is likely to be a $200 billion market by 2026? Plus further opportunities that could be developed if the B Cell Platform works as hoped.
Ann: New mimotope cancer vaccine results published, page-26
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.6¢ |
Change
-0.004(6.67%) |
Mkt cap ! $411.5M | |||
| Open | High | Low | Value | Volume |
| 5.9¢ | 5.9¢ | 5.5¢ | $1.481M | 26.09M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 400000 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 685507 | 4 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |